Wall Street brokerages expect Hologic, Inc. (NASDAQ:HOLX) to report $782.88 million in sales for the current quarter, according to Zacks. Five analysts have provided estimates for Hologic’s earnings, with the lowest sales estimate coming in at $780.40 million and the highest estimate coming in at $784.30 million. Hologic posted sales of $734.40 million during the same quarter last year, which suggests a positive year over year growth rate of 6.6%. The business is expected to report its next quarterly earnings report on Wednesday, February 7th.

On average, analysts expect that Hologic will report full-year sales of $782.88 million for the current year, with estimates ranging from $3.23 billion to $3.34 billion. For the next fiscal year, analysts expect that the firm will report sales of $3.41 billion per share, with estimates ranging from $3.37 billion to $3.45 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Hologic.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.01. Hologic had a net margin of 24.70% and a return on equity of 21.69%. The company had revenue of $802.90 million during the quarter, compared to the consensus estimate of $792.54 million. During the same period in the previous year, the firm posted $0.52 EPS. The firm’s revenue was up 10.5% compared to the same quarter last year.

A number of research firms have recently issued reports on HOLX. Piper Jaffray Companies reaffirmed a “buy” rating and set a $48.00 price objective on shares of Hologic in a report on Thursday, November 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $50.00 price objective on shares of Hologic in a report on Friday, November 3rd. Zacks Investment Research raised shares of Hologic from a “sell” rating to a “hold” rating in a report on Tuesday, October 31st. Jefferies Group reaffirmed a “buy” rating and set a $44.00 price objective (down from $49.00) on shares of Hologic in a report on Tuesday, October 10th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $45.00 price objective (down from $48.00) on shares of Hologic in a report on Monday, October 9th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have issued a buy rating to the company’s stock. Hologic presently has a consensus rating of “Buy” and an average price target of $47.54.

Shares of Hologic (HOLX) opened at $41.85 on Tuesday. Hologic has a fifty-two week low of $35.76 and a fifty-two week high of $46.80. The company has a current ratio of 0.79, a quick ratio of 0.61 and a debt-to-equity ratio of 0.79. The stock has a market cap of $11,261.67, a price-to-earnings ratio of 20.22, a PEG ratio of 1.97 and a beta of 0.95.

In other Hologic news, Director Lawrence M. Levy sold 9,596 shares of the business’s stock in a transaction on Tuesday, October 10th. The shares were sold at an average price of $36.81, for a total value of $353,228.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Lawrence M. Levy sold 7,139 shares of the business’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $39.04, for a total transaction of $278,706.56. The disclosure for this sale can be found here. Insiders sold 35,972 shares of company stock valued at $1,385,977 over the last three months. 0.79% of the stock is currently owned by insiders.

Institutional investors have recently bought and sold shares of the business. Hall Laurie J Trustee raised its stake in shares of Hologic by 10.2% during the second quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock valued at $110,000 after acquiring an additional 225 shares during the last quarter. Commonwealth Bank of Australia raised its stake in shares of Hologic by 31.0% during the second quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock valued at $114,000 after acquiring an additional 600 shares during the last quarter. Grove Bank & Trust raised its stake in shares of Hologic by 115.8% during the third quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock valued at $105,000 after acquiring an additional 1,535 shares during the last quarter. National Asset Management Inc. bought a new position in shares of Hologic during the second quarter valued at about $203,000. Finally, Cambridge Investment Research Advisors Inc. bought a new position in shares of Hologic during the second quarter valued at about $213,000. 98.09% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “$782.88 Million in Sales Expected for Hologic, Inc. (HOLX) This Quarter” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/12/05/782-88-million-in-sales-expected-for-hologic-inc-holx-this-quarter-2.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Get a free copy of the Zacks research report on Hologic (HOLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.